Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – ...

"Our vision is simple - we want to bring 100% of $REEF home to Reef Chain, where it can be most impactful,” said Derek E. Silva, Operations Lead at Reef. "Reef ...

We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to ...